|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 14/705 | |
| C07K 19/00 | |||
| C12N 5/10 | |||
| A61K 38/17 |
| (11) | Number of the document | 1141248 |
| (13) | Kind of document | T |
| (96) | European patent application number | 99967350.2 |
| Date of filing the European patent application | 1999-12-16 | |
| (97) | Date of publication of the European application | 2001-10-10 |
| (45) | Date of publication and mention of the grant of the patent | 2011-12-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US1999/029873 |
| Date | 1999-12-16 |
| (87) | Number | WO 2000/036092 |
| Date | 2000-06-22 |
| (30) | Number | Date | Country code |
| 112752 P | 1998-12-17 | US |
| (72) |
BROWNING, Jeffrey, US
MIATKOWSKI, Konrad, US
MEIER, Werner, US
|
| (73) |
Biogen Idec MA Inc.,
14 Cambridge Center, Cambridge, Massachusetts 02142,
US
|
| (54) | A METHOD FOR THE HIGH LEVEL EXPRESSION OF THE ACTIVE FORM OF LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS AND THEIR PURIFICATION |
| A METHOD FOR THE HIGH LEVEL EXPRESSION OF THE ACTIVE FORM OF LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS AND THEIR PURIFICATION |